Welcome to our dedicated page for Lianbio news (Ticker: LIANY), a resource for investors and traders seeking the latest updates and insights on Lianbio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lianbio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lianbio's position in the market.
LianMedical (OTC Pink: LIANY), formerly known as LianBio, announced completion of the previously approved merger between LianBio and LianMedical. The Merging Company (LianMedical) was merged into LianBio, with LianBio surviving and immediately changing its name to LianMedical.
Headquartered in Shanghai, the Company will focus on developing and commercializing innovative medical devices, targeting significant unmet clinical needs and expanding patient access to global technologies in China and other Asia Pacific markets. The Company has begun generating commercial revenue from initial product activities. Each ordinary share of the Merging Company was exchanged for 68.3775 ordinary shares of the Company, with fractions rounded up, while existing LianBio ordinary shares continue as fully paid ordinary shares of the Company. The Company’s American Depositary Shares continue trading on the OTC Pink under the symbol “LIANY”.